Abstract
Metabolic syndrome, a “cluster” of metabolic disorders including hypertension, increases the cardiovascular risk, and insulin resistance plays a key role in its pathogenesis. In this syndrome antihypertensive treatment with betablockers is underused because of their adverse metabolic effects. The aim was to review the evidences supporting the reasons for under-using beta-blockers in hypertensive patients with metabolic syndrome. A review of Literature has been carried out via PubMed from 1998 to 2008: most of beta-blockers have adverse effects on insulin sensitivity, carbohydrate and lipid metabolism, and are not recommended in metabolic syndrome. However, some recent large studies have shown a better metabolic profile with newer third generation vasodilating beta-blockers, such as Carvedilol and Nebivolol. Vasodilating action of Carvedilol and Nebivolol, due respectively to alpha1-blocking effect and release of nitric oxide, explains the lack of adverse metabolic effects of these beta-blockers that could also be used in hypertensive patients with metabolic syndrome.
Keywords: Antihypertensive, Beta-blockers, Metabolic syndrome
Current Diabetes Reviews
Title: Antihypertensive Treatment with Beta-Blockers in the Metabolic Syndrome: A Review
Volume: 6 Issue: 4
Author(s): Angelo M. Carella, Giuseppe Antonucci, Matteo Conte, Michele Di Pumpo, Armando Giancola and Elisabetta Antonucci
Affiliation:
Keywords: Antihypertensive, Beta-blockers, Metabolic syndrome
Abstract: Metabolic syndrome, a “cluster” of metabolic disorders including hypertension, increases the cardiovascular risk, and insulin resistance plays a key role in its pathogenesis. In this syndrome antihypertensive treatment with betablockers is underused because of their adverse metabolic effects. The aim was to review the evidences supporting the reasons for under-using beta-blockers in hypertensive patients with metabolic syndrome. A review of Literature has been carried out via PubMed from 1998 to 2008: most of beta-blockers have adverse effects on insulin sensitivity, carbohydrate and lipid metabolism, and are not recommended in metabolic syndrome. However, some recent large studies have shown a better metabolic profile with newer third generation vasodilating beta-blockers, such as Carvedilol and Nebivolol. Vasodilating action of Carvedilol and Nebivolol, due respectively to alpha1-blocking effect and release of nitric oxide, explains the lack of adverse metabolic effects of these beta-blockers that could also be used in hypertensive patients with metabolic syndrome.
Export Options
About this article
Cite this article as:
M. Carella Angelo, Antonucci Giuseppe, Conte Matteo, Di Pumpo Michele, Giancola Armando and Antonucci Elisabetta, Antihypertensive Treatment with Beta-Blockers in the Metabolic Syndrome: A Review, Current Diabetes Reviews 2010; 6 (4) . https://dx.doi.org/10.2174/157339910791658844
DOI https://dx.doi.org/10.2174/157339910791658844 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Aspects in Sustained Drug Release Formulations
Recent Patents on Drug Delivery & Formulation Epistatic Control of Human Obesity as Revealed by Linkage Disequili-brium Mapping: A Report from the NHLBI-Sponsored WISE Study
Current Genomics Differential ERK1/2 Signaling and Hypertrophic Response to Endothelin-1 in Cardiomyocytes from SHR and Wistar-Kyoto Rats: A Potential Target for Combination Therapy of Hypertension
Current Vascular Pharmacology Adrenomedullin in Hypertension and Obesity
Current Hypertension Reviews Oxidative-Nitrosative Stress In Hypertension
Current Vascular Pharmacology Mending a Broken Heart: Bioengineered Patches and Scaffolds for Cardiac Repair
Recent Patents on Biomedical Engineering (Discontinued) Anesthetic Considerations for Electroconvulsive Therapy-Especially Hemodynamic and Respiratory Management
Current Psychiatry Reviews Novel Validated RP-HPLC Method for Simultaneous Estimation of Valsartan & Gliclazide in Bulk and Dosage Forms
Current Pharmaceutical Analysis Postpartum Haemorrhage, A Persisting Killer Around the Globe, Road Ahead
Current Women`s Health Reviews HS-MMGKG: A Fast Multi-objective Harmony Search Algorithm for Two-locus Model Detection in GWAS
Current Bioinformatics Xanthine Oxidase Inhibitor Febuxostat as a Novel Agent Postulated to Act Against Vascular Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Effects of N-Acetyl-L-Cysteine and Hyaluronic Acid on HBOC-201- Induced Systemic and Cerebral Vasoconstriction in the Rat
Current Drug Discovery Technologies Role of Calcitonin Gene-Related Peptide in Gastric Mucosal Defence and Healing
Current Pharmaceutical Design Cardiovascular Diseases and Natural Products
Current Protein & Peptide Science Renal Heat Shock Proteins Over-Expression Due to Anabolic Androgenic Steroids Abuse
Mini-Reviews in Medicinal Chemistry Subject Index to Volume 4
Current Drug Targets - Cardiovascular & Hematological Disorders The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research P2Y Purinoceptors as Potential Emerging Therapeutical Target in Vascular Disease
Current Pharmaceutical Design Tacrine Derivatives and Alzheimers Disease
Current Medicinal Chemistry Role of Endothelin in Diabetic Retinopathy
Current Vascular Pharmacology